Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
PTGX 
Protagonist Therapeutics Inc (PTGX)
Top performer
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/22/2025: PTGX (5-star) is a STRONG-BUY. BUY since 43 days. Simulated Profits (27.87%). Updated daily EoD!
Upturn Star Rating
Outstanding Performance
These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.
Number of Analysts
10 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $76.46
1 Year Target Price $76.46
| 5 | Strong Buy |
| 4 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 105.02% | Avg. Invested days 58 | Today’s Advisory Regular Buy |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 10/22/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 4.82B USD | Price to earnings Ratio 102.74 | 1Y Target Price 76.46 |
Price to earnings Ratio 102.74 | 1Y Target Price 76.46 | ||
Volume (30-day avg) 10 | Beta 2.2 | 52 Weeks Range 33.31 - 93.25 | Updated Date 10/22/2025 |
52 Weeks Range 33.31 - 93.25 | Updated Date 10/22/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.73 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 24.88% | Operating Margin (TTM) -758.04% |
Management Effectiveness
Return on Assets (TTM) 2.25% | Return on Equity (TTM) 8.61% |
Valuation
Trailing PE 102.74 | Forward PE 26.39 | Enterprise Value 3483305443 | Price to Sales(TTM) 23.05 |
Enterprise Value 3483305443 | Price to Sales(TTM) 23.05 | ||
Enterprise Value to Revenue 16.65 | Enterprise Value to EBITDA 129.79 | Shares Outstanding 62211318 | Shares Floating 43158480 |
Shares Outstanding 62211318 | Shares Floating 43158480 | ||
Percent Insiders 1.02 | Percent Institutions 116.23 |
Upturn AI SWOT
Protagonist Therapeutics Inc
Company Overview
History and Background
Protagonist Therapeutics Inc. was founded in 2006. It is a biopharmaceutical company focused on discovering and developing peptide-based new chemical entities (NCEs) to address unmet medical needs.
Core Business Areas
- Oral Peptide Therapeutics: Development of oral peptide therapeutics for inflammatory bowel disease (IBD) and other gastrointestinal (GI) diseases.
- Injectable Peptide Therapeutics: Development of injectable peptide therapeutics for hematological and other disorders.
Leadership and Structure
Dinesh V. Patel, Ph.D., is the President and CEO. The company has a board of directors and a management team overseeing research and development, clinical trials, and business operations.
Top Products and Market Share
Key Offerings
- Rusfertide (PTG-300): An injectable hepcidin mimetic for the treatment of polycythemia vera (PV). Currently in Phase 3 clinical trials. Revenue generation is projected upon successful completion of trials and regulatory approval. Competitors include traditional phlebotomy and cytoreductive agents like hydroxyurea, as well as other emerging therapies targeting PV.
- PN-943: An oral, gut-restricted alpha-4-beta-7 integrin antagonist in Phase 2 clinical trials for ulcerative colitis. Competitors include anti-TNF therapies (e.g., Humira, Remicade), anti-integrins (e.g., Entyvio), and JAK inhibitors (e.g., Xeljanz) and S1P receptor modulators (Zeposia).
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high research and development costs, long development timelines, and stringent regulatory requirements. The market for IBD and hematological disorders is growing due to increasing prevalence and improved diagnostics.
Positioning
Protagonist Therapeutics is positioned as an innovator in peptide-based therapeutics, focusing on oral delivery and targeted therapies. Its competitive advantage lies in its proprietary peptide technology platform.
Total Addressable Market (TAM)
The TAM for PV and IBD therapies is substantial, estimated in the billions of dollars annually. Protagonist is aiming to capture a portion of this market with its novel therapeutics.
Upturn SWOT Analysis
Strengths
- Proprietary peptide technology platform
- Experienced management team
- Pipeline of differentiated product candidates
- Strong intellectual property position
Weaknesses
- Reliance on clinical trial success
- High cash burn rate
- Competition from established pharmaceutical companies
- Limited commercialization experience
Opportunities
- Potential for strategic partnerships
- Expansion of pipeline into new indications
- Positive clinical trial results
- Regulatory approvals
Threats
- Clinical trial failures
- Regulatory setbacks
- Competition from biosimilars
- Economic downturn
Competitors and Market Share
Key Competitors
- INCY
- BMY
- MRK
- PFE
Competitive Landscape
Protagonist Therapeutics competes with large pharmaceutical companies in specific therapeutic areas. Its advantage lies in its novel peptide technology, while its disadvantage is its smaller size and resources.
Growth Trajectory and Initiatives
Historical Growth: Growth has been driven by advancement of clinical programs and strategic partnerships.
Future Projections: Future growth is dependent on successful clinical trial outcomes and regulatory approvals. Analyst estimates vary based on pipeline potential.
Recent Initiatives: Recent initiatives include advancing Rusfertide through Phase 3 trials and expanding the PN-943 program.
Summary
Protagonist Therapeutics is a biotech company with a promising peptide-based technology platform. The success of the company hinges on the clinical trial outcomes of its key product candidates, particularly Rusfertide and PN-943. Competition is stiff, and the company's limited commercialization experience presents a risk. Strategic partnerships and pipeline expansion are key to long-term growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
- ClinicalTrials.gov
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Market conditions and company performance are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Protagonist Therapeutics Inc
Exchange NASDAQ | Headquaters Newark, CA, United States | ||
IPO Launch date 2016-08-11 | CEO, President, Secretary & Director Dr. Dinesh V. Patel Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 130 | Website https://www.protagonist-inc.com |
Full time employees 130 | Website https://www.protagonist-inc.com | ||
Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide therapeutics for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide, an injectable mimetic of hepcidin that is in phase 3 clinical trials for the treatment of polycythemia vera; Icotrokinra, an orally delivered investigational drug which is in phase 3 clinical trials indicated to block biological pathways targeted by marketed injectable antibody drugs; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company also develops IL-17 oral peptide antagonist PN-88,1 an oral metabolic/obesity peptide program, and an oral hepcidin mimetic/ferroportin blocker that is in pre-clinical stage. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.